S-1: Profusa Launches Public Offering Amid Going Concern Doubts

Profusa, Inc. announces a best-efforts public offering of up to $45 million in units, pre-funded units, and warrants to fund operations and repay debt, while facing significant financial challenges and Nasdaq listing compliance issues.

Summary

• Profusa, Inc. is offering up to 5,102,040 units at an assumed price of $2.94 per unit, each consisting of one common stock share and two warrants, or pre-funded units for purchasers exceeding beneficial ownership limits.
• The offering aims to raise approximately $14.6 million in net proceeds, which will be allocated as $12.3 million for working capital and general corporate purposes, and $2.3 million for repayment of outstanding debt to Tasly.
• The company has a history of net losses, including $27.3 million for the nine months ended September 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Profusa has expressed substantial doubt about its ability to continue as a going concern, citing recurring losses and negative cash flows.
• The company received notices from Nasdaq regarding non-compliance with minimum bid price ($1.00), market value of listed securities ($50 million), and market value of publicly held shares ($15 million) requirements.
• A 1-for-75 reverse stock split was effected on February 9, 2026, to regain compliance with the minimum bid price requirement.
• Profusa entered into a know-how license agreement with Mayo Foundation for Medical Education and Research on February 11, 2026, for continuous oxygen measurement and critical limb-threatening ischemia.
• The company received approval for forgiveness of its $1,304,996.05 Paycheck Protection Program (PPP) loan on February 11, 2026.
• Profusa's Lumee Oxygen Platform has CE Mark approval in the EU and is undergoing clinical trials for FDA approval in the U.S., with commercialization in Europe anticipated in early 2026 and U.S. launch in late 2026.
• The Lumee Glucose Platform, a continuous glucose monitoring (CGM) system, is in clinical trials with proof-of-concept data showing a mean absolute relative difference (MARD) of approximately 11% over nine months, and regulatory submission in early 2026 is anticipated.
• The company's intellectual property portfolio includes 25 issued U.S. patents and 32 rest-of-world patents, expiring between March 2030 and January 2040.
• Profusa has a bitcoin treasury strategy, having purchased $2.0 million (16.51 Bitcoins) as of the filing date, which exposes it to high volatility and regulatory risks.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial distress, including substantial net losses, a going concern warning, and multiple Nasdaq listing deficiencies. While product development and a new license are positive, they are overshadowed by the urgent need for capital and the high dilution risk of the current offering.

Positives

• Secured a know-how license agreement with Mayo Foundation for Medical Education and Research for continuous oxygen measurement and critical limb-threatening ischemia, enhancing product development and commercialization potential.
• Received approval for the full forgiveness of a $1,304,996.05 PPP loan, improving the company's financial position by eliminating this debt.
• Lumee Oxygen Platform has CE Mark approval in the EU, with commercialization efforts expected to begin in early 2026, providing a near-term revenue opportunity.
• Lumee Glucose Platform has generated promising proof-of-concept clinical data from 54 diabetes subjects, demonstrating potential for long-term continuous glucose monitoring with a MARD of approximately 11% and no device-related serious adverse events.
• Possesses a substantial intellectual property portfolio with 25 issued U.S. patents and 32 rest-of-world patents, providing protection for its biointegrated sensor technology.
• The company's technology platform is designed to offer a cost-effective and user-friendly solution for real-time individual biochemistry monitoring, potentially expanding the addressable market significantly beyond current solutions.

Negatives

• Incurred significant net losses, with $27.3 million for the nine months ended September 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Reported a working capital deficit of approximately $19.3 million as of September 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Received multiple notices from Nasdaq regarding non-compliance with continued listing requirements, including minimum bid price, market value of listed securities, and market value of publicly held shares.
• The public offering is on a 'best-efforts' basis with no minimum amount required to be sold, meaning the company may not raise sufficient capital to meet its business plans.
• Purchasers in the offering will incur immediate and substantial dilution of $11.44 per share in net tangible book value.
• Lumee Glucose is not yet authorized for commercial sale in any jurisdiction, and Lumee Oxygen requires FDA approval for U.S. commercialization, creating regulatory and market entry uncertainties.
• The company's bitcoin treasury strategy exposes it to high volatility and significant legal, commercial, regulatory, and technical uncertainties, which could adversely impact financial results and stock price.
• Outstanding promissory notes and convertible notes, including a matured Tasly convertible note, pose liquidity risks, with some notes currently in default.

Risks

• This is a best-efforts offering with no minimum amount of units required to be sold, potentially leading to insufficient capital for business plans.
• Management has broad discretion over the use of net proceeds, which may not be invested successfully.
• Immediate and substantial dilution in net tangible book value for new investors ($11.44 per share).
• Substantial doubt about the company's ability to continue as a going concern, which may hinder future financing.
• Risk of delisting from Nasdaq due to non-compliance with minimum bid price, market value of listed securities, and market value of publicly held shares requirements.
• Operating in a highly competitive market with large, well-established companies possessing significant resources.
• Exposure to risks from international operations, including local product preferences, longer payment cycles, foreign currency fluctuations, and less intellectual property protection.
• Consumer confusion about oxygen monitoring and CGM products could lead to lower sales or negative publicity.
• High reliance on Lumee Oxygen Platform for commercial revenue until additional products receive regulatory approval.
• Dependence on third-party suppliers and outsourced parties, leading to vulnerability to supply disruptions, suboptimal quality, noncompliance, and price fluctuations.
• No guarantee of FDA 510(k) clearance or PMA approval for products, which would adversely affect business growth.
• Clinical trials are lengthy, expensive, and have uncertain outcomes; earlier study results may not predict future success.
• Products may cause or contribute to adverse medical events or malfunctions, requiring FDA reporting and potentially leading to sanctions or recalls.
• Quality problems could lead to recalls, safety alerts, and reputational harm.
• Potential claims of infringement or misappropriation of others' intellectual property rights, leading to costly litigation, licensing requirements, or product redesigns.
• Identified material weaknesses in internal control over financial reporting, which could affect accurate and timely financial reporting and stock price.
• Environmental, social, and corporate governance (ESG) regulations may complicate the supply chain and affect customer relationships.
• Bitcoin treasury strategy exposes the company to high volatility, regulatory developments in crypto assets, and counterparty risks with custodians, potentially leading to loss of value.
• Inadequate funding for regulatory agencies (FDA, SEC) could delay product development or commercialization.
• Potential long-term complications from products under development may not be revealed by current clinical experience.
• Subject to federal, state, and foreign laws prohibiting kickbacks and false claims, and other fraud and abuse laws, which could lead to substantial penalties.
• Changes to the regulatory landscape may impact the ability to obtain marketing authorization for future product developments.
• Failure to protect intellectual property could allow competitors to produce similar products, impairing competitive ability.
• Inability to adequately protect trade secrets could diminish technology value.
• Patent terms may be inadequate to protect competitive position for a sufficient time.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Intellectual property rights may not address all potential threats or be effective globally.
• Manufacturing difficulties or disruptions at facilities could adversely affect operations and sales.
• Customer or third-party complaints or negative publicity could harm reputation and brand.
• The estimated addressable market size may be smaller than anticipated.
• Disasters could adversely affect business, and continuity plans may be inadequate.
• Operating results may fluctuate significantly, making future predictions difficult.
• Inability to establish and maintain adequate sales and marketing capabilities or partnerships.
• Increased costs and additional regulations as a public company.
• Reduced disclosure requirements as an emerging growth company may make shares less attractive to investors.
• Risk of non-performance by counterparties in the bitcoin treasury strategy.
• Regulatory change reclassifying bitcoin as a security could lead to classification as an investment company under the 1940 Act.
• Temporary or permanent blockchain forks could adversely affect the business.
• Due diligence procedures to mitigate transaction risk with sanctioned entities may fail.
• The concentration of bitcoin holdings enhances inherent risks of the treasury strategy.
• Emergence or growth of other digital assets could negatively impact bitcoin price.
• Bitcoin holdings are less liquid than cash and may not serve as a reliable source of liquidity.
• Security breaches or cyberattacks related to bitcoin holdings could result in loss of bitcoin.

Future Outlook

Profusa anticipates launching the Lumee Oxygen Platform in Europe in early 2026 and seeking U.S. FDA marketing authorization for it in late 2026. The Lumee Glucose Platform is expected to begin its next validation study in the first half of 2026, with regulatory submission in early 2026 and U.S. approval in late 2026 or early 2027. The company plans a dual strategy for Lumee Glucose commercialization, targeting both direct-to-hospital and direct-to-pharmacy sales. Future product revenues are also expected from other analytes (lactate, CO2, ethanol, pH) and from data stream partnerships with telemedicine and health and wellness coaching sectors.

Management Comments

• Management believes that Lumee Glucose's ability to provide continuous glucose monitoring with only an initial single injection is an attractive alternative for people with diabetes.
• Management believes that Lumee's biosensor and artificial intelligence platform compares very attractively with some of the largest products in this market sector.
• Management believes its validated core technology can easily bridge the gap that exists in the current technology landscape for monitoring real time biochemistry.
• Management believes that the growth of telemedicine and coaching platforms suffer from the lack of real time clinical data, and Profusa's platform could be the indispensable data stream to support this vision.

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive and rapidly evolving digital health and medical technology sectors, particularly continuous glucose monitoring (CGM) and oxygen monitoring. The company's strategy to develop biointegrated sensors for long-term, real-time biochemistry data aligns with broader industry trends towards personalized medicine, remote patient monitoring (RPM), and technology-enabled healthcare. The market for CGM and oxygen monitoring is substantial, estimated at over $2.8 billion and $2 billion in the U.S. respectively by 2024. Profusa's focus on user-friendly, cost-effective, and long-lasting sensors aims to differentiate it from existing solutions like Abbott's Libre, Medtronic's Guardian Connect, and Senseonics' Eversense E3, which often require more frequent sensor replacement or invasive surgical implantation. The pursuit of partnerships in telemedicine and health and wellness coaching reflects a strategic move to integrate its data streams into high-growth healthcare sectors, capitalizing on the increasing demand for real-time clinical data to enhance AI-driven platforms and improve clinical utility.

Comparison to Industry Standards

• Profusa's Lumee Glucose platform has demonstrated potential for a mean absolute relative difference (MARD) of approximately 11% with up to nine months of functionality post-injection. This compares to existing CGM solutions like Dexcom G6, Abbott Freestyle Libre 2, Medtronic Guardian Connect, and Senseonics Eversense E3, which typically have shorter sensor lifespans (7-14 days for needle-type CGMs, 12 months for surgically implanted ones like Eversense E3) and varying MARD values (e.g., Dexcom G6 at ~9%, Freestyle Libre 2 at ~9.2%). Profusa aims to offer a substantially better user-friendly form factor and longer functionality.
• The Lumee Oxygen Platform competes with devices using transcutaneous oximetry (TCPO2) from companies like Perimed AB, Radiometer Medical, and SenTec AG, as well as doppler or cuff devices measuring Ankle-Brachial Index (ABI), Toe-Brachial Index (TBI), or Segmental Pressure Values (SPP). Profusa's system offers direct measurement of oxygen availability in interstitial fluid at target depths, providing insights into acute and chronic tissue oxygen levels, which may offer a more precise and continuous monitoring solution compared to some existing methods.
• Profusa's strategy to decouple the sensor and reader elements aims for lower system cost and reusability of the more expensive reader component, potentially offering a competitive pricing advantage over current CGM solutions that often have high costs limiting insurance reimbursement to only the most severe diabetes patients.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation, arbitration, or governmental proceeding is currently pending against the company or its management team.
• The company is currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million accrued.

Related Party Transactions

• Tasly Convertible Debt: Profusa entered into a short-term loan agreement with Tasly (a shareholder) in June 2023, borrowing up to $1.6 million. The loan bears 12% annual interest (24% default rate) and matured on December 31, 2023, extended to March 31, 2024, and is currently in default. As of September 30, 2025, the fair value was $2.1 million.
• Ascent Partners Fund LLC (Ascent): Entered into a PIPE Subscription Agreement on February 11, 2025, for senior secured convertible notes up to $22,222,222 principal amount ($20,000,000 purchase price). Initial note of $10,000,000 principal issued on July 11, 2025, and a second tranche of $2,222,222 principal issued on September 30, 2025. Also entered into an Equity Line of Credit (ELOC) Purchase Agreement on July 28, 2025, allowing the sale of up to $100,000,000 of common stock to Ascent. Issued Commitment Warrants to Ascent to purchase 12,000 shares of common stock.
• NorthView Acquisition Corp. (Sponsor): Assumed a convertible working capital promissory note from NorthView with the Sponsor for up to $2.5 million. The note is non-interest bearing and became convertible on July 11, 2025. As of September 30, 2025, the outstanding principal was $1,919,796.
• The Founders: Two of the company's founders provided $0.2 million in promissory notes in 2010 and 2011, accruing 5% annual interest with no set maturity date. Additional short-term promissory notes of $0.3 million were borrowed from founders in 2022 (partially repaid) and $0.3 million from an existing investor in 2023. As of September 30, 2025, $0.9 million in promissory notes were outstanding, with some in default.

Stakeholder Impact

• Shareholders: Face significant dilution from the current offering and potential future equity raises. Existing shareholders will experience immediate and substantial dilution in net tangible book value. The ongoing Nasdaq listing issues pose a risk of delisting, which could negatively impact share price and liquidity. The volatility of the bitcoin treasury strategy also introduces risk to shareholder value.
• Employees: The company's ability to attract and retain skilled personnel is crucial for future success, especially in research, development, manufacturing, and sales. Failure to manage growth effectively could lead to loss of employees and reduced productivity. Executive officers have severance arrangements.
• Customers: The success of Lumee Oxygen and Lumee Glucose depends on market acceptance and regulatory approvals. Delays or failures in commercialization could limit product availability and impact patient care. Consumer confusion about product features and safety issues with competitive products could also affect adoption.
• Creditors: The company's 'going concern' doubt and existing defaults on promissory notes and the Tasly convertible debt indicate heightened risk for creditors. The repayment of outstanding debt is a priority for the proceeds of the current offering.
• Regulatory Authorities: The company is subject to extensive pre-market and post-market regulation by the FDA and other international bodies. Non-compliance could lead to penalties, product recalls, and restrictions on operations. The company's clinical trial processes are under regulatory oversight.

Next Steps

• Complete the current best-efforts public offering by March 4, 2026, to raise necessary capital.
• Regain compliance with Nasdaq's Minimum Bid Price, Market Value of Listed Securities, and Market Value of Publicly Held Shares requirements by March 10, 2026, and April 27, 2026, respectively.
• Initiate commercialization efforts for the Lumee Oxygen Platform in Europe in early 2026.
• Start the next validation study for the Lumee Glucose Platform in the first half of 2026.
• Submit for regulatory approval of Lumee Glucose in early 2026.
• Seek FDA marketing authorization for Lumee Oxygen in the U.S. by late 2026.
• Seek FDA approval for Lumee Glucose in the U.S. in late 2026 or early 2027.
• Continue discussions with investors to establish the APAC Joint Venture.
• Develop and add to Profusa's product portfolio to tackle the management of other chronic conditions using its core technology.
• Strategically engage in commercial B2B relationships to capture portions of the coaching, telemedicine, and health and wellness segments.
• Implement and verify any design changes for a next generation of Lumee Oxygen, submitting additional performance data or proof of equivalency to FDA.

Key Dates

Recommendation

Profusa faces severe financial challenges, including substantial and increasing net losses, a significant working capital deficit, and an explicit 'going concern' warning from management and auditors. The company is also in non-compliance with multiple Nasdaq listing requirements, risking delisting. While the public offering aims to raise capital, it is a 'best-efforts' offering with no guarantee of sufficient funds, and it will cause immediate and substantial dilution for investors. The company's bitcoin treasury strategy adds another layer of high volatility and regulatory risk. Despite promising product development in biointegrated sensors, the overwhelming financial and operational risks, coupled with the uncertainty of regulatory approvals and commercialization success, make this a highly speculative and precarious investment. A seasoned investor would likely view the current situation as indicative of severe underlying issues that outweigh any potential future upside, warranting a strong sell recommendation.

Keywords

Biointegrated Sensors, Continuous Glucose Monitoring (CGM), Lumee Oxygen Platform, Lumee Glucose Platform, Medical Devices, Digital Health Technology, SEC Filing, Public Offering, Warrants, Pre-funded Warrants, Nasdaq Listing, Going Concern, Clinical Trials, FDA Approval, CE Mark, Intellectual Property, Bitcoin Treasury Strategy, Capital Raise, Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI), Diabetes Management, Telemedicine, Health and Wellness Coaching, Biomarkers, Financial Reporting, Risk Management